总归，虽然受新冠肺炎疫情的影响，二零二零年高血压范畴依然获得了许多令人鼓舞和振作的研讨作用，一起还有许多有争议的问题仍需求进一步研讨。
别的有关肠道微生物菌群与高血压、人工智能及互联网+在高血压办理范畴的运用等，也是未来高血压学科开展的远景方向。信任在2021年，咱们在逐渐打败疫情的一起，在高血压范畴也能获得更多的作用。
参考文献
[1]Chao Gao, Yue Cai , Kan Zhang, et al. Association of hypertension and antihypertensive treatment with COVID-19 mortality: a retrospective observational study. Eur Heart J, 2020, 41: 2058–2066.
[2]Francisco J de Abajo, Sara Rodríguez-Martín,Victoria Lerma, et al. Use of renin–angiotensin–aldosterone system inhibitors and risk of COVID-19 requiring admission to hospital: a case-population study. Lancet, 2020, 395: 1705-1714.
[5]Lopes RD, Macedo AVS, de Barros E Silva PGM, et al. Effect of Discontinuing vs Continuing Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockerson Days Alive and Out of the Hospital in Patients Admitted With COVID-19: A Randomized Clinical Trial. JAMA, 2021, 325(3): 254-264.
[6]Antihypertensive Drugs and COVID-19 Risk: A Cohort Study of 2 Million Hypertensive Patients. Hypertension. 2021 Jan 11.
[7]Thomas Unger, Claudio Borghib ,Fadi Charchar, et al. 2020 International Society of Hypertension Global Hypertension Practice Guidelines. Hypertension, 2020. 75(6): 1334-1357.
[8]D Canoy, E Copland, R Ramakrishnan, et al. Stratified effects of blood pressure-lowering treatment on long-term blood pressure: an individual patient-level meta-analysis involving 50 randomised trials and 334, 219 participants. EurHeart J, 2020, 41(Suppl_2): ehaa946.2762.
[9] Selvaraj S, Claggett BL, Böhm M, et al. Systolic Blood Pressure in Heart Failure With Preserved Ejection Fraction Treated With Sacubitril/Valsartan. J Am Coll Cardiol, 2020, 75(14): 1644-1656.
[10] Pardeep S Jhund, Alice M, Marc A Pfeffer, et al. Sacubitril/valsartan as a Treatment for Resistant Hypertension in Patients With Heart Failure and Preserved Ejection Fraction. Circulation, 2020,142(Suppl_3): A16477.
[11]Ito S, Itoh H, Rakugi H, et al. Double-Blind Randomized Phase 3 Study Comparing Esaxerenone (CS-3150) and Eplerenone in Patients With Essential Hypertension (ESAX-HTN Study). Hypertension, 2020, 75(1): 51-58.
[12]Verweij P, Danaietash P, Flamion B, et al. Randomized Dose-Response Study of the New Dual Endothelin Receptor Antagonist Aprocitentan in Hypertension. Hypertension, 2020, 75(4): 956-965.
[13]Böhm M, Kario K, Kandzari DE, et al. Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal): a multicentre, randomised, sham-controlled trial. Lancet, 2020, 395(10234): 1444-1451.
[14]Mulatero P, Monticone S, Deinum J, et al. Genetics, prevalence, screening and confirmation of primary aldosteronism: a position statement and consensus of the Working Group on Endocrine Hypertension of The European Society of Hypertension. J Hypertens, 2020, 38(10): 1919-1928.
[15]Mulatero P, Sechi LA, Williams TA, et al. Subtype diagnosis, treatment, complications and outcomes of primary aldosteronism and future direction of research: a position statement andconsensus of the Working Group on Endocrine Hypertension of the European Society of Hypertension. J Hypertens, 2020, 38(10): 1929-1936.
[16]Kario K, Hoshide S, MizunoH, et al. Nighttime Blood Pressure Phenotype and Cardiovascular Prognosis: Practitioner-Based Nationwide JAMP Study. Circulation, 2020, 142(19): 1810-1820.
[19]Hokyou Lee, et al. Cardiovascular Risk of Isolated Systolic or Diastolic Hypertension in Young Adults. Circulation, 2020, 141: 1778–1786.
转载：请标明“我国循环杂志”
许多疑问杂乱病例,一个医师 终身 也只能见到 一次
再获荣誉！我国循环杂志主办“阜外说心脏”当选国家新闻出书署
数字出书精品遴选引荐方案
日前，国家新闻出书署发布了数字出书精品遴选引荐方案二零二零年度当选项目，此次共有46个项目当选，“阜外说心脏”位列其间！
二零一八年，经国家卫生健康委宣传司评选，“阜外说心脏”曾当选国家卫生健康委品牌活动引荐名单。
“阜外说心脏”系列患者教育节目，由国家心血管病中心、我国医学科学院阜外医院辅导，《我国循环杂志》主办。
“阜外说心脏”节目以“锵锵三人行”的对话方法进行健康教育，并结合 网络直播和微信大众号的方法，向广阔心血管疾病患者供给科学、标准、风趣、靠谱的心血管疾病自我办理常识。
